H.C. Wainwright initiated coverage of NRx Pharmaceuticals (NRXP) with a Buy rating and $40 price target the company is combining novel therapeutics with integrated mental health care delivery to address acute suicidality in depression, the analyst tells investors in a research note. The firm believes NRx is positioned to become a leader in high-isk mood disorders and remains “significantly undervalued” at current share levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXP:
- NRx Pharmaceuticals (NASDAQ: NRXP) Secures FDA Fast Track for IV Ketamine Formulation NRX-100 in Suicidal Depression
- NRx Pharmaceuticals presents two keynote talks at 2025 Global Passion Project
- NRx Pharmaceuticals’ Earnings Call Highlights Strategic Progress
- NRx Pharmaceuticals (NASDAQ: NRXP) Announces Expanded Access Policy for NRX-100 Following FDA Fast Track Designation
- NRx Pharmaceuticals announces expanded access policy for NRX-100